Interview: CD34+ Cells in Cell and Gene Therapy Process Development

To view the interview, please login to your account.

No account yet? Register.

In this interview Dr. Manon Destalminil, Bioprocessing Project Leader at CellProthera, discusses the advantages of using our research-grade CD34+ cells for cell and gene therapy process development.

Dr. Destalminil explains

• how using commercially available CD34+ cells helped CellProthera optimize their process and save crucial patient samples
• why researchers should use mobilized CD34+ cells as opposed to other conventions
• what characteristics are needed when using frozen cells
• which advancements she would most like to see in this space Register to read or download the interview now.

Register now to read or download the interview. 

Would you like to receive updates? Subscribe to our cell and gene therapy eNews to stay tuned on new educational content or product and applications news.

Would you like to learn more about our CD34+ cells or our broad portfolio of blood and immune cells and tissues?